Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
A phase 2 trial of clonoSEQ in Multiple myeloma, run by Washington University School of Medicine, now recruiting.
Overview
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance is a phase 2 interventional study registered as NCT06483100 by Washington University School of Medicine, with 65 participants planned, started 2024-12-20 and due to reach its primary completion in 2032-06-30. Interventions recorded: Elrantamab, clonoSEQ. Conditions recorded: Multiple Myeloma.
Linked to the drug clonoSEQ because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Shares clonoSEQ and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialGlofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Shares clonoSEQ and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Shares Multiple myeloma and the tag pipeline.
- TrialPamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.